Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.


Related Content

Actelion Gets Early Benefits From Savings Plan, Awaits Opsumit Decision
Actelion Defends PAH Franchise With Generics And Second-Generation Drugs
Swedish Boost For Life Sciences Innovation Resonates Around Europe
Big Pharma's EU Woes Continued In Second Quarter - Where’s The Bottom?
Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter
Merck KGAA Begins Transformation Effort By Closing Geneva Site
Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame
R&D Restructurings Aim To Placate Investors While Pharma Waits For Results
Actelion, GSK Scrap Sleep Drug Almorexant


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts